{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:09:54Z","timestamp":1793740194568,"version":"4.6.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["15\/57\/66"],"award-info":[{"award-number":["15\/57\/66"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunotherapy is revolutionising the treatment of patients diagnosed with melanoma and other cancers. The first immune checkpoint inhibitor, ipilimumab (targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)), showed a survival advantage over standard chemotherapy. Subsequently the anti-programmed cell death protein 1 (PD-1) antibodies, nivolumab and pembrolizumab were shown to be more effective than ipilimumab. Ipilimumab combined with nivolumab gives an incremental gain in overall survival compared with nivolumab alone but increases the risk of severe, potentially life-threatening toxicities. In contrast to ipilimumab monotherapy, anti-PD-1 antibodies are licensed to be continued until disease progression. Follow-up of patients recruited to the first trials evaluating 2\u2009years of pembrolizumab showed that three-quarters of responding patients continue responding after stopping treatment. Suggestive of early response, we hypothesised that continuing anti-PD-1 treatment beyond 1\u2009year in progression-free patients may be unnecessary and so designed the DANTE trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>DANTE is a multicentre, randomised, phase III, non-inferiority trial to evaluate the duration of anti-PD-1 therapy in patients with metastatic (unresectable stage III and stage IV) melanoma. It uses a two-stage recruitment strategy, registering patients before they complete 1\u2009year of first-line anti-PD-1 +\/\u2212 CTLA-4 therapy and randomising eligible patients who have received 12\u2009months of treatment and are progression-free at 1\u2009year. At randomisation, 1208 patients are assigned (1:1) to either 1) continue anti-PD-1 treatment until disease progression\/ unacceptable toxicity\/ for at least 2\u2009years in the absence of disease progression\/ unacceptable toxicity or 2) to stop treatment. Randomisation stratifies for baseline prognostic factors. The primary outcome is progression-free survival at 3, 6, 9 and 12\u2009months and then, 6-monthly for up to 4-years. Secondary outcomes collected at all timepoints include overall survival, response-rate and duration and safety, with quality of life and cost-effectiveness outcomes collected 3-monthly for up to 18-months. Sub-studies include a qualitative analysis of patient acceptance of randomisation and sample collection to inform future translational studies into response\/ toxicity biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>DANTE is a unique prospective trial investigating the optimal duration of anti-PD-1 therapy in metastatic melanoma patients. Outcomes will inform future use of these high burden drugs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.isrctn.com\/ISRCTN15837212\">ISRCTN15837212<\/jats:ext-link>, 31 July 2018.\u00a0<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08509-w","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T09:03:26Z","timestamp":1625130206000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma"],"prefix":"10.1186","volume":"21","author":[{"given":"Oliver","family":"Coen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pippa","family":"Corrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Ottensmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Hook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurdeep S.","family":"Sagoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Meads","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Bestall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Velikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdia A.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eszter","family":"Katona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shobha","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Collinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Rodwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3593-2890","authenticated-orcid":false,"given":"Sarah","family":"Danson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,1]]},"reference":[{"issue":"10","key":"8509_CR1","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","volume":"351","author":"H Tsao","year":"2004","unstructured":"Tsao H, Atkins MB, Sober AJ. Management of Cutaneous Melanoma. N Engl J Med. 2004;351(10):998\u20131012. https:\/\/doi.org\/10.1056\/NEJMra041245.","journal-title":"N Engl J Med"},{"issue":"26","key":"8509_CR2","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","volume":"364","author":"C Robert","year":"2011","unstructured":"Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus Dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1104621.","journal-title":"N Engl J Med"},{"issue":"3","key":"8509_CR3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332. https:\/\/doi.org\/10.1016\/S1470-2045(14)70012-9.","journal-title":"Lancet Oncol"},{"issue":"14","key":"8509_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey L, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356. https:\/\/doi.org\/10.1056\/NEJMoa1709684.","journal-title":"N Engl J Med"},{"issue":"10027","key":"8509_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2015","unstructured":"Herbst RS, Baas P, Dong-Wan K, Felip E, Per\u00e9z-Gracia J, Han J, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015;387(10027):1540\u201350. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7.","journal-title":"Lancet."},{"issue":"19","key":"8509_CR6","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"R Ferris","year":"2016","unstructured":"Ferris R, Blumenschein G, Fayette J, Guigay J, Colevas D, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375(19):1856\u201367. https:\/\/doi.org\/10.1056\/NEJMoa1602252.","journal-title":"N Engl J Med"},{"issue":"14","key":"8509_CR7","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","volume":"378","author":"RJ Motzer","year":"2018","unstructured":"Motzer RJ, Tannir NM, McDermott DF, Frontera OA, Melichar B, Choueiri TK, et al. Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277\u201390. https:\/\/doi.org\/10.1056\/NEJMoa1712126.","journal-title":"N Engl J Med"},{"issue":"3","key":"8509_CR8","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radke A, Baron A, Necchi A, Bedke J, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18(3):312\u201322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7.","journal-title":"Lancet Oncol"},{"issue":"2","key":"8509_CR9","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in Cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205\u201314. https:\/\/doi.org\/10.1016\/j.cell.2015.03.030.","journal-title":"Cell."},{"issue":"8","key":"8509_CR10","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with Ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1003466.","journal-title":"N Engl J Med"},{"issue":"8","key":"8509_CR11","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","volume":"16","author":"A Ribas","year":"2015","unstructured":"Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908\u201318. https:\/\/doi.org\/10.1016\/S1470-2045(15)00083-2.","journal-title":"Lancet Oncol"},{"issue":"4","key":"8509_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375\u201384. https:\/\/doi.org\/10.1016\/S1470-2045(15)70076-8.","journal-title":"Lancet Oncol"},{"issue":"16","key":"8509_CR13","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Loa CD, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1910836.","journal-title":"N Engl J Med"},{"issue":"4","key":"8509_CR14","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdz011.","journal-title":"Ann Oncol"},{"key":"8509_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","volume":"134","author":"O Nigro","year":"2020","unstructured":"Nigro O, Pinotti G, De Galitiis F, Di Pietro FR, Giusti R, Filetti M, et al. Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: a multicentre study. Eur J Cancer. 2020;134:19\u201328. https:\/\/doi.org\/10.1016\/j.ejca.2020.04.025.","journal-title":"Eur J Cancer"},{"key":"8509_CR16","volume-title":"Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)","author":"National Institute for Health and Care Excellence","year":"2015","unstructured":"National Institute for Health and Care Excellence. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366). 2015. https:\/\/www.nice.org.uk\/guidance\/ta366\/resources\/pembrolizumab-for-advanced-melanoma-not-previously-treated-with-ipilimumab-pdf-82602732133573. Accessed 15 Nov 2020."},{"key":"8509_CR17","volume-title":"Nivolumab for the treatment of advanced (unresectable or metastatic) melanoma (TA384)","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. Nivolumab for the treatment of advanced (unresectable or metastatic) melanoma (TA384). 2016. https:\/\/www.nice.org.uk\/guidance\/ta384\/resources\/nivolumab-for-treating-advanced-unresectable-or-metastatic-melanoma-pdf-82602849706693. Accessed 15 Nov 2020."},{"key":"8509_CR18","volume-title":"Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400)","author":"National Institute for Health and Care Excellence","year":"2016","unstructured":"National Institute for Health and Care Excellence. Nivolumab in combination with ipilimumab for treating advanced melanoma (TA400). 2016. https:\/\/www.nice.org.uk\/guidance\/ta400\/resources\/nivolumab-in-combination-with-ipilimumab-for-treating-advanced-melanoma-pdf-82604536041157. Accessed 15 Nov 2020."},{"issue":"Suppl 5","key":"8509_CR19","doi-asserted-by":"publisher","first-page":"abstr55","DOI":"10.1200\/JCO.2020.38.5_suppl.55","volume":"38","author":"PG Corrie","year":"2020","unstructured":"Corrie PG, Chao D, Board R, Lawton S, Smittenaar R. Metastatic melanoma patients outcomes since introduction of immune checkpoint inhibitors in England between 2014 and 2018. J Clin Oncol. 2020;38(Suppl 5):abstr55.","journal-title":"J Clin Oncol"},{"key":"8509_CR20","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. N Engl J Med. 2019;20:1239. https:\/\/doi.org\/10.1016\/S1470-2045(19)30388-2.","journal-title":"N Engl J Med"},{"issue":"17","key":"8509_CR21","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1200\/JCO.2017.77.0412","volume":"36","author":"S Gettinger","year":"2018","unstructured":"Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, et al. Five-year follow-up of Nivolumab in previously treated advanced non\u2013small-cell lung Cancer: results from the CA209-003 study. J Clin Oncol. 2018;36(17):1675\u201384. https:\/\/doi.org\/10.1200\/JCO.2017.77.0412.","journal-title":"J Clin Oncol"},{"issue":"8","key":"8509_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41416-019-0570-y","volume":"121","author":"S Danson","year":"2019","unstructured":"Danson S, Hook J, Marshall H, Smith A, Bell S, Rodwell S, et al. Are we over-treating with checkpoint inhibitors? Br J Cancer. 2019;121(8):629\u201330. https:\/\/doi.org\/10.1038\/s41416-019-0570-y.","journal-title":"Br J Cancer"},{"issue":"2","key":"8509_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"8509_CR24","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-CT075","volume-title":"Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-na\u00efve patients with advanced melanoma (CheckMate 067)","author":"J Larkin","year":"2017","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, et al. Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-na\u00efve patients with advanced melanoma (CheckMate 067). Washington DC: American Association for Cancer Research; 2017."},{"key":"8509_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A. Quality of life research within the EORTC\u2014the EORTC QLQ-C30. Eur J Cancer. 2002;38:125\u201333. https:\/\/doi.org\/10.1016\/S0959-8049(01)00448-8.","journal-title":"Eur J Cancer"},{"issue":"1","key":"8509_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/CMR.0000000000000122","volume":"25","author":"JB Winstanley","year":"2015","unstructured":"Winstanley JB, Young TE, Boyle FM, Bergenmar M, Bottomley A, Burmeister B, et al. Cross-cultural development of a quality-of-life measure for patients with melanoma. Melanoma Res. 2015;25(1):47\u201358. https:\/\/doi.org\/10.1097\/CMR.0000000000000122.","journal-title":"Melanoma Res"},{"issue":"10","key":"8509_CR27","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727\u201336. https:\/\/doi.org\/10.1007\/s11136-011-9903-x.","journal-title":"Qual Life Res"},{"key":"8509_CR28","volume-title":"National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0","author":"National Cancer Institute","year":"2017","unstructured":"National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 15 Nov 2020."},{"key":"8509_CR29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2015.08.007","volume":"69","author":"JM Giesinger","year":"2016","unstructured":"Giesinger JM, Kieffer JM, Fayers PM, Groenvold M, Peterson MA, Scott NW, et al. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust. J Clin Epidemiol. 2016;69:79\u201388. https:\/\/doi.org\/10.1016\/j.jclinepi.2015.08.007.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"8509_CR30","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B Van Hout","year":"2012","unstructured":"Van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15(5):708\u201315. https:\/\/doi.org\/10.1016\/j.jval.2012.02.008.","journal-title":"Value Health"},{"issue":"12","key":"8509_CR31","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","volume":"32","author":"R Faria","year":"2014","unstructured":"Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157\u201370. https:\/\/doi.org\/10.1007\/s40273-014-0193-3.","journal-title":"Pharmacoeconomics."},{"issue":"8","key":"8509_CR32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40273-018-0650-5","volume":"36","author":"B Leurent","year":"2018","unstructured":"Leurent B, Gomes M, Faria R, Morris S, Grieve R, Carpenter JR. Sensitivity analysis for not-at-random missing data in trial-based cost-effectiveness analysis: a tutorial. Pharmacoeconomics. 2018;36(8):889\u2013901. https:\/\/doi.org\/10.1007\/s40273-018-0650-5.","journal-title":"Pharmacoeconomics."},{"issue":"5","key":"8509_CR33","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1177\/0272989X12454577","volume":"32","author":"JJ Caro","year":"2012","unstructured":"Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM modeling good research practices task force\u20131. Med Decis Mak. 2012;32(5):667\u201377. https:\/\/doi.org\/10.1177\/0272989X12454577.","journal-title":"Med Decis Mak"},{"issue":"5","key":"8509_CR34","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/j.1524-4733.2008.00358.x","volume":"11","author":"GR Barton","year":"2008","unstructured":"Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value Health. 2008;11(5):886\u201397. https:\/\/doi.org\/10.1111\/j.1524-4733.2008.00358.x.","journal-title":"Value Health"},{"key":"8509_CR35","volume-title":"Research methods for clinical and health psychology","author":"H Joffe","year":"2004","unstructured":"Joffe H, Yardley L. Content and thematic analysis. In: Marks DF, Yardley L, editors. Research methods for clinical and health psychology. London: Sage; 2004."},{"issue":"3","key":"8509_CR36","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137. https:\/\/doi.org\/10.7326\/0003-4819-158-3-201302050-00583.","journal-title":"Ann Intern Med"},{"issue":"Suppl 5","key":"8509_CR37","first-page":"abstr 12970","volume":"28","author":"D Spigel","year":"2017","unstructured":"Spigel D, McCleod M, Hussein M, Waterhouse DM, Einhorn L, Horn L, et al. Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28(Suppl 5):abstr 12970.","journal-title":"Ann Oncol"},{"key":"8509_CR38","doi-asserted-by":"publisher","unstructured":"Baetz T, Song X, Ernst DS, McWhirter E, Petrella TM, Savage KJ, et al. A randomized phase III study of duration of anti-PD-1 therapy in metastatic melanoma (STOP-GAP): Canadian Clinical Trials Group study (CCTG) ME.13. J Clin Oncol. 2018. https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.TPS9600.","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9600"},{"key":"8509_CR39","volume-title":"Netherlands trial register","author":"University Medical Centre Utrecht","year":"2018","unstructured":"University Medical Centre Utrecht. Netherlands trial register. 2018. https:\/\/www.trialregister.nl\/trial\/7293. Accessed 15 Nov 2020."},{"issue":"7","key":"8509_CR40","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","volume":"30","author":"YJL Jansen","year":"2019","unstructured":"Jansen YJL, Rozeman EA, Mason R, Goldinger SM, Geukes Foppan MH, Hoejberg L, et al. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. Ann Oncol. 2019;30(7):1154\u201361. https:\/\/doi.org\/10.1093\/annonc\/mdz110.","journal-title":"Ann Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08509-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08509-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T09:04:27Z","timestamp":1625130267000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08509-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8509"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08509-w","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,1]]},"assertion":[{"value":"9 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial is being performed in accordance with the World Medical Association Declaration of Helsinki and UK ethical approval has been granted by the National Research Ethics Service (reference: \/EM\/0440). Each participating site is required to approve the trial via a site-specific assessor prior to entering participants into the trial. All participants are required to provide informed written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"PC has received speaker fees and sat on advisory boards for MSD, BMS, Novartis and Pierre Fabre. RP has received conference and travel support from MSD and BMS; and sat on advisory boards or received speaker fees from BMS, Pierre Faber and Novartis. FG has consulted for AstraZeneca and has research funding from GSK. SR is CEO of charity Melanoma Focus. SD has received conference and travel support from MSD, Pierre Fabre and BMS; and sat on advisory boards for MSD and BMS. The remaining authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"761"}}